Addictive disorders represent a complex interplay of genetic, environmental, and psychological factors, leading individuals to engage in compulsive behaviors despite negative outcomes. Substance use disorders, including alcoholism, opioid addiction, and stimulant abuse, are among the most well-known manifestations. However, behavioral addictions like gambling disorder and internet gaming disorder are increasingly recognized for their significant impact on individuals' lives. At the core of addictive disorders lies a dysregulation of the brain's reward system, wherein repeated exposure to addictive substances or behaviors leads to neuroadaptations that reinforce continued engagement. This cycle of craving, consumption, and withdrawal perpetuates the addictive cycle, making it challenging for individuals to abstain even in the face of adverse consequences. Treatment approaches for addictive disorders vary but often encompass a combination of pharmacotherapy, psychotherapy, and behavioral interventions. Medications may help manage cravings and withdrawal symptoms, while therapy aims to address underlying psychological issues and teach coping strategies for managing triggers and urges. Support groups such as Alcoholics Anonymous and Narcotics Anonymous provide valuable peer support and encouragement throughout the recovery journey. Overall, addressing addictive disorders requires a comprehensive and personalized approach that considers the unique needs and circumstances of each individual.
Title : Perception and individuality in patient cases identifying the ongoing evolution of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)
Ken Ware, NeuroPhysics Therapy Institute, Australia
Title : Narrative medicine: A communication therapy for the communication disorder of Functional Seizures (FS) [also known as Psychogenic Non-Epileptic Seizures (PNES)]
Robert B Slocum, University of Kentucky HealthCare, United States
Title : Personalized and Precision Medicine (PPM), as a unique healthcare model through biodesign-driven biotech and biopharma, translational applications, and neurology-related biomarketing to secure human healthcare and biosafety
Sergey Victorovich Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Neuro sensorium
Luiz Moutinho, University of Suffolk, United Kingdom
Title : GBF1 inhibition reduces amyloid-beta levels in viable human postmortem Alzheimer's disease cortical explant and cortical organoid models
Sean J Miller, Yale School of Medicine, United States
Title : Traumatic Spinal Cord Injuries (tSCI) - Are the radiologically based “advances” in the management of the injured spine evidence-based?
W S El Masri, Keele University, United Kingdom